Wang Xin
Clinical trials sponsored by Wang Xin, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Precision radiation plus immunotherapy shows promise for bile duct cancer Results expected Sep 2026 (estimated)
-
Can radiotherapy and poop pills outsmart liver cancer resistance?
Disease control Recruiting nowThis Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …
Phase 2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Precision radiation plus immunotherapy shows promise for bile duct cancer
Disease control Recruiting nowThis study tests a new approach for advanced bile duct cancer, combining a precise type of radiation (PULSAR) with immunotherapy drugs and chemotherapy. The goal is to see if this combination is safe and effective. The trial is recruiting 60 adults aged 18-75 with confirmed bile …
Phase 1/2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC